
SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA
SEOUL,South Korea,Jan. 10,2025-- SNBioScience today announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a